ATE506439T1 - Codon-optimisierte hiv-rt-nef-gag dna impfstoffe - Google Patents
Codon-optimisierte hiv-rt-nef-gag dna impfstoffeInfo
- Publication number
- ATE506439T1 ATE506439T1 AT02798748T AT02798748T ATE506439T1 AT E506439 T1 ATE506439 T1 AT E506439T1 AT 02798748 T AT02798748 T AT 02798748T AT 02798748 T AT02798748 T AT 02798748T AT E506439 T1 ATE506439 T1 AT E506439T1
- Authority
- AT
- Austria
- Prior art keywords
- nef
- codone
- fragment
- dna vaccines
- hiv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 101710177291 Gag polyprotein Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2001/004207 WO2002024225A1 (en) | 2000-09-20 | 2001-09-20 | Use of immidazoquinolinamines as adjuvants in dna vaccination |
| GB0129604A GB0129604D0 (en) | 2001-12-11 | 2001-12-11 | Novel compounds |
| GB0206462A GB0206462D0 (en) | 2002-03-19 | 2002-03-19 | Vaccines |
| PCT/EP2002/010592 WO2003025003A2 (en) | 2001-09-20 | 2002-09-18 | Hiv-gag codon-optimised dna vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE506439T1 true ATE506439T1 (de) | 2011-05-15 |
Family
ID=43927344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02798748T ATE506439T1 (de) | 2001-09-20 | 2002-09-18 | Codon-optimisierte hiv-rt-nef-gag dna impfstoffe |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR101067231B1 (de) |
| AT (1) | ATE506439T1 (de) |
| DE (1) | DE60239815D1 (de) |
| MY (1) | MY131949A (de) |
| TW (1) | TWI329647B (de) |
| ZA (1) | ZA200402189B (de) |
-
2002
- 2002-09-18 DE DE60239815T patent/DE60239815D1/de not_active Expired - Lifetime
- 2002-09-18 KR KR1020047004128A patent/KR101067231B1/ko not_active Expired - Fee Related
- 2002-09-18 AT AT02798748T patent/ATE506439T1/de not_active IP Right Cessation
- 2002-09-20 MY MYPI20023515A patent/MY131949A/en unknown
- 2002-09-20 TW TW091121625A patent/TWI329647B/zh not_active IP Right Cessation
-
2004
- 2004-03-18 ZA ZA2004/02189A patent/ZA200402189B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI329647B (en) | 2010-09-01 |
| MY131949A (en) | 2007-09-28 |
| DE60239815D1 (de) | 2011-06-01 |
| ZA200402189B (en) | 2005-07-27 |
| KR20040039387A (ko) | 2004-05-10 |
| HK1066830A1 (en) | 2005-04-01 |
| KR101067231B1 (ko) | 2011-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003025003A3 (en) | Hiv-gag codon-optimised dna vaccines | |
| MY145614A (en) | Vaccine | |
| BR0010361A (pt) | Seq ências genÈmicas de neisseria e uso destas | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1108638T1 (el) | Πρωτεϊνη συντηξης των hiv ρυθμιστικων/επικουρικων πρωτεϊνων | |
| NO991078L (no) | HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV | |
| EA200700904A1 (ru) | Вакцины против вируса японского энцефалита и вируса западного нила | |
| DE69941049D1 (de) | Retrovirales verabreichungssystem | |
| DK0640133T3 (da) | Rekombinante DNA-molekyler, der koder for aminopeptidaseenzymer og deres anvendelse i fremstillingen af vacciner mod helmin | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| ATE420183T1 (de) | Antigen-konstrukte, für den nachweis und die unterscheidung von antikörpern gegen hiv | |
| TW200502245A (en) | Vaccine | |
| DE69840326D1 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
| ATE506439T1 (de) | Codon-optimisierte hiv-rt-nef-gag dna impfstoffe | |
| WO2003089571A3 (en) | Ehrlichia canis genes and vaccines | |
| WO2002022663A3 (en) | Stress resistant retroviruses | |
| DE60040219D1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
| WO2003052122A3 (en) | Gp41 inhibitor | |
| EP1578772A4 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
| DE60235223D1 (de) | Streptococcus pyogenes polypeptide und entsprechende dna fragmente | |
| ATE414905T1 (de) | Diabetesmodell | |
| EP1129177A4 (de) | Avipox-vektor, der für ein hiv-antigen und ein zytokin kodiert. | |
| WO2004027066A3 (fr) | Protéine recombinante chimérique et diagnostic in vitro du hiv | |
| DK1553977T3 (da) | Vaccine mod infektioner med onkogene vira, såsom Felin Leukæmi Virus hos katte | |
| DE60133455D1 (de) | G-protein gekoppelter rezeptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |